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Cochrane and the COMET initiative: developing the 
evidence base in oral medicine
J. Taylor,*1,2 T. Walsh,2 H. Worthington,2 P. Brocklehurst,3 M. N. Pemberton2,4 and A. M. Glenny2
of oral features such as swollen and friable 
gingivae and spontaneous gingival haemor-
rhage. At the time it was a common disease 
among long distance sailors. Lind’s work 
identified the superiority of the citrus fruits 
over other proposed treatments and, although 
recognised as important, it took more than 
40 years before the results of Lind’s experi-
ments were acted upon; this time lag between 
research findings and changes in practice is still 
apparent today.2
This paper will briefly explore how the use 
of research evidence has developed since then 
to inform clinical practice focusing on oral 
medicine. It will also introduce the concept of 
core outcome sets to help improve future trial 
data reporting to allow comparison, contrast 
and combination as appropriate.
Despite the historic use of evidence in 
informing practice, the term ‘evidence-based 
practice’ (EBP) is relatively new, appearing 
initially as evidence-based medicine in 1992. 
Over the years EBP has evolved to mean many 
things to many people. Perhaps the most fre-
quently used and feasible definition of EBP 
(first applied to evidence-based medicine) is: 
Evidence-based practice
The concept of using research evidence to 
inform healthcare involving oral medicine, 
has a long history. One of the earliest accounts 
of research being undertaken to explore 
treatment options is the comparative clinical 
trial reported in James Lind’s Treatise of the 
scurvy, published in 1753.1 Lind was a surgeon 
on HMS Salisbury. His book details his com-
parison of interventions for the treatment and 
prevention of scurvy, along with a critical and 
chronological account of what had been pre-
viously published on scurvy. Scurvy has mul-
tisystem manifestations including a number 
All clinicians in medicine and dentistry aim to deliver evidence-based practice; however, it is widely recognised that the 
current evidence base for interventions in oral medicine, as with many other specialties, is of a low quality. The highest level 
of evidence is considered to be the systematic review and meta-analysis. The Cochrane Collaboration and the Cochrane Oral 
Health group produce high quality systematic reviews, however, despite the large number of trials carried out for treatments 
in oral medicine, the results are often not able to be utilised to guide clinical care due to the various methodological 
limitations of the trials including the heterogeneity of outcome measures used. To improve the strength of the evidence 
base this will need to change. The Comet initiative aims to support the development of core outcome sets which are used 
to allow homogeneity of outcome measures in trials and therefore will allow pooling of data for meta-analysis in future 
systematic reviews. This paper explores the complexities involved in producing evidence for oral medicine interventions and 
introduces an approach for developing core outcome sets in oral medicine.
‘The conscientious, explicit and judicious use 
of current best evidence in making decisions 
about the care of individual patients.’3
EBP is not about applying the results of 
research to all clinical settings and all patients 
without careful thought and evaluation. 
Instead it promotes the integration of best 
available research evidence with the individual 
clinician’s experience and clinical judgement. 
In addition to this, the patient’s expectations 
and preferences need to be taken into the 
decision-making process; a factor often not 
considered. Only when research evidence, 
clinical expertise and patient values are con-
sidered together can practice be considered 
evidence-based.
Clearly, in order to practice EBP, there needs 
to be a strong evidence base. That is, there 
needs to be relevant, valid research. Despite 
the promotion of EBP over the last 30 years, it 
has been estimated that only 15% of all clinical 
practice is based on sound research evidence.4 
Variations in practice and the provision of 
inappropriate care continue. The incorporation 
of research evidence into the clinical decision 
making process may be hampered by several 
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factors,5 not least the lack of reliable research 
addressing a clinical issue.
It has been suggested that the most 
realistic use of EBP by practitioners at the 
point of care involves the use of summaries 
of research evidence.5 Sources of secondary 
research, such as systematic reviews and 
clinical guidelines, may indeed have an 
important role to play in helping to close the 
gap between research evidence and clinical 
practice,2 providing they themselves are well 
conducted, address a clinically important 
question and that there are reliable studies 
addressing the specified questions.
The Cochrane Collaboration
One organisation aiming to improve the use 
of research evidence in clinical practice is 
The Cochrane Collaboration. Cochrane is a 
global independent network of researchers, 
professionals, patients, carers, and people 
interested in health. There are more than 
37,000 contributors from over 130 countries. 
They aim to produce credible, accessible health 
information that is free from commercial 
sponsorship and other conflicts of interest. 
Cochrane believe the need to produce high-
quality systematic reviews of research evidence 
is of increasing importance: ‘As access to health 
evidence increases, so do the risks of misin-
terpreting complex content; meanwhile the 
likelihood of any one person getting a complete 
and balanced picture decreases’ (http://www.
cochrane.org/about-us). Cochrane is inter-
nationally recognised as the benchmark for 
high-quality information about the effective-
ness of healthcare. It focuses predominantly, 
but not exclusively, on systematic reviews 
of randomised controlled trials (RCTs). It is 
acknowledged, however, that RCTs may not be 
the most appropriate study design to evaluate 
every clinical research question. Clinicians, 
policy makers and researchers need to be 
able to recognise the merits of different study 
designs in primary research for answering 
different types of clinical questions (whether 
they deal with evaluating the effectiveness of 
preventative or therapeutic interventions, the 
diagnosis of a particular disease or condition, 
incidence or prevalence, or perhaps cost-effec-
tiveness of a defined management strategy).6
Cochrane Oral Health (COH)
Cochrane is made up of over 50 Review 
Groups, of which COH is one (http://
oralhealth.cochrane.org).7 The scope of 
COH is to undertake systematic reviews 
(predominantly of randomised controlled 
trials) covering the prevention, treatment 
and rehabilitation of oral, dental and crani-
ofacial diseases and disorders. The group has 
a worldwide network of over 1650 members 
from 42 different countries. It maintains a 
register of references to clinical trials within 
the scope of the group. This register currently 
contains around 33,000 references. To date, 
COH have 154 published systematic reviews 
and 45 protocols. Their reviews have been used 
to inform guideline development by organisa-
tions such as the National Institute of Clinical 
Excellence (NICE), the Scottish Intercollegiate 
Network (SIGN), the American Dental 
Association and the Scottish Dental Clinical 
Effectiveness Programme (SDCEP).
COH are committed to producing high-
quality reviews that address priority clinical 
questions. They are currently working on an 
international priority setting exercise to ensure 
they address questions that are most useful 
for informing clinical decision-making by 
consumers and clinicians alike. In a previous 
COH prioritisation exercise carried out in 
2014, oral medicine conditions featured in 
two distinct areas:
1. Oral cancer (screening, diagnostic tests, 
clinical assessment)
2. Oral conditions (temporomandibular 
disorders (TMD), lichen planus, leukopla-
kia, denture stomatitis).
In undertaking the reviews, COH are keen 
to ensure they work closely with all relevant 
stakeholders, in particular guideline develop-
ers, to ensure there is minimal duplication of 
effort and maximum uptake of the findings 
from their systematic reviews.
Oral medicine and evidence base
There are a number of Cochrane reviews in 
the field of oral medicine, covering a variety of 
topics (see Table 1). A key criticism of Cochrane 
reviews, particularly within dentistry, is that 
there are insufficient trials for the reviews to 
be useful. However, in the majority of oral 
medicine reviews, this is not the case with the 
number of trials included in the latest versions 
of the reviews ranging from 10–131. Despite 
the large number of trials in oral medicine, the 
results produced are often too heterogeneous 
to be utilised to inform clinical practice.
For example, with regard to recurrent 
aphthous stomatitis (RAS), there are over 25 
trials in a review evaluating systemic interven-
tions and 77 trials to date in an ongoing review 
evaluating topical interventions.8 The evidence 
base presented in each review is limited by 
several factors. Firstly, there is a wide range of 
interventions being assessed. Twenty-five trials 
of systemic interventions provide evidence on 
21 different interventions; 77 trials of topical 
interventions provide evidence on over 60 
interventions. In most cases, each intervention 
was assessed in only a single trial; where more 
than one trial evaluated the same intervention 
there was variation in dose and duration of the 
intervention and choice of control group. Such 
clinical heterogeneity precludes pooling of data. 
Often, interventions were evaluated with little 
clinical justification or discussion of biological 
plausibility and suggested mode of action.
In addition, there was substantial heteroge-
neity in type and timing of outcome assess-
ment. When evaluating ulcers, this outcome 
was reported variously as number of ulcers, 
number of episodes, duration of ulcers/healing 
time, complete healing, size of ulcers, presence 
of ulcers, erythema, ooedema, exudation, 
compound/summated RAS index, ulcer 
severity, site of ulcers, effectiveness index, onset 
of prodromal phase and recurrence. Other 
outcomes evaluated include pain (measured in 
a variety of ways), eating and drinking experi-
ence, brushing experience, tolerability/satis-
faction with medication, recovery of function, 
adherence, and daily activity disturbance. The 
timing of assessments also varied. Some trials 
reported single episodes of ulceration and 
others reported multiple episodes (present-
ing data either cumulatively or per episode). 
Timeframes were as short as eight hours or 
as long as six months. In some cases, timing 
of outcome measurement was unspecified, 
or based around daily function (for example, 
before/after meal times). Unless the primary 
time point of interest is clearly specified 
a priori, there is potential for the reporting and 
interpretation of results to be data driven, that 
is, according to the time point that provides 
the most favourable result rather than at the 
time point which is of clinical interest or 
importance.
To assess the risk of bias in trials the 
Cochrane Risk of Bias Assessment tool 
was used (covering selection, performance, 
detection, attrition and reporting biases).9 Out 
of all 102 trials evaluated to date within the two 
systematic reviews, only one was considered to 
be at low risk of bias overall.10 One of the main 
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areas of potential bias was selective reporting. 
Trials were assessed as being at risk of selective 
reporting bias due to the lack of reporting of 
important, expected outcomes (for example, 
pain), lack of reporting of outcomes listed in 
the methods section, outcomes reported but 
not at all listed time points, or summary sta-
tistics reported without measures of variability.
Issues regarding lack of accounting for mul-
tiplicity following measurement at many time 
points and reporting at an ulcer level rather 
than a person level were also apparent, as was 
analysis within the intervention and compara-
tor groups over time, rather than comparing 
the groups at a specified time point.
The use of composite scales, providing a 
summated score based on categorical scores 
on a range of clinical domains (for example, 
number of ulcers, size, duration, ulcer-free 
period, site and pain) were also problematic. 
Unless scores for individual components are 
also provided, it is difficult to interpret the 
findings as improvement could be due to 
changes in any one of the domains measured 
or a composite. It is recognised that there is no 
cure for RAS and therefore all treatments are 
used to alleviate symptoms. The assessment of 
their impact therefore is best carried out by 
the patients themselves. The use of patient 
reported outcome measures is an important 
area to consider in RAS and many other oral 
medicine conditions. The use of a validated 
quality of life tool to assess the impact of 
chronic oral disease would be beneficial as 
described by Ni Riordain et al.11
Other limitations were apparent in the RAS 
evidence base, often linked to poor reporting. 
Although no formal assessment on reporting 
has been undertaken, there does not appear 
to be any consistent improvement in the 
conduct and reporting of RAS trials over time. 
Recent trials still lack clarity with regard to the 
inclusion/exclusion of participants within the 
trials, with the definition of RAS not always 
being apparent or whether individuals with 
systemic causes of RAS type lesions had been 
excluded. Many trials are limited in size, 
often with insufficient participants to be able 
to observe a statistically significant effect of 
treatment in the trial between interventions if 
one truly existed.
The Cochrane reviews of RAS are not the 
only reviews to have highlighted limitations of 
the evidence base in this area. Baccaglini et al. 
undertook a systematic review of RAS inter-
ventional trials published from 2005 to 2011.12 
They identified considerable methodological 
flaws in the trial designs. They concluded, 
‘Improved design, analysis and standard-
ised reporting of clinical trials are needed to 
maximise study quality, disclose potential 
sources of bias, and ensure complete assess-
ment of product safety and effectiveness.’
These limitations are not isolated to RAS 
trials. Clinical trials in other areas of oral 
medicine have also been compromised due 
to methodological factors.13 Two recent 
systematic reviews assessing interventions 
for mucocutaneous pemphigus vulgaris 
(PV) and mucous membrane pemphigoid 
(MMP), carried out as part of the Sixth World 
Workshop of Oral Medicine (WWOM VI) 
and published in 2014, also concluded that 
there was inadequate quality of research 
supporting optimal PV treatment and a lack 
of high-quality research providing evidence-
based MMP treatments.14,15 Both reviews 
revealed numerous methodological limita-
tions including heterogeneity of outcome 
measures used.
Future trials
Several steps can be undertaken to help 
overcome the limitations identified. A number 
of these steps are clearly described in a recent 
paper by Innes et al.16 Prospective registration 
of trial protocols can help overcome issues 
of reporting biases, specifically outcome 
reporting bias. Careful attention needs to 
be given to the choice of intervention being 
evaluated; interventions should be relevant to 
current practice and compared with appro-
priate controls (that is, not sub-clinical doses 
of alternative treatments). Trials should be 
methodologically rigorous in their design and 
fully reported according to the CONSORT 
statement (www.consort-statement.org).
While single treatment interventions are 
the most common type of trial design, they 
do not necessarily reflect how the intervention 
is used within everyday practice, which often 
utilises multiple and/or sequential approaches 
to treatment. This has the potential to reduce 
the external validity of the study and so other 
types of trial design should be considered (for 
example, n-of-1 and stepped interventions) at 
the design stage.
In addition to examining the effective-
ness of interventions, future studies should 
incorporate an appropriate economic evalu-
ation. As stated in the Cochrane Handbook,17 
the usefulness and applicability of Cochrane 
reviews can be enhanced by incorporating 
economics perspectives. Future trials should 
consider calculating and reporting the costs 
of interventions evaluated in order to better 
inform healthcare decision-making.
Outcome sets & the COMET initiative
Importantly, given the huge variation in the 
choice of outcomes measured, a set of standard-
ised, clinically relevant outcome measures needs 
to be developed across different topic areas 
within oral medicine. As described below, this 
work is currently underway for RAS, registered 
Table 1  Oral-medicine-related Cochrane reviews
Review Review type Number of RCTs
Interventions for preventing/treating oral mucositis for patients 
with cancer receiving treatment Effectiveness
131 trials of prevention; 
32 trials of treatment
Interventions for preventing/treating oral 
candidiasis for patients with cancer receiving treatment Effectiveness
28 trials of prevention; 
10 trials of treatment
Interventions for treating oral lichen planus Effectiveness 28
Interventions for treating oral leukoplakia Effectiveness 14
Diagnostic tests for oral cancer and potentially malignant disor-
ders in patients presenting with clinically evident lesions
Diagnostic test 
accuracy 41
Clinical assessment to screen for the detection of oral cavity 
cancer and potentially malignant disorders in apparently healthy 
adults (N = 13)
Diagnostic test 
accuracy 13
Systemic interventions for the management of recurrent 
aphthous stomatitis (mouth ulcers) Effectiveness 25
Interventions for the management of oral ulcers in Behçet’s 
Disease Effectiveness 14
Topical interventions for the management of recurrent aphthous 
stomatitis (mouth ulcers) Effectiveness
Ongoing review, 77 
trials included to date
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with COMET (core outcome measures in effec-
tiveness trials; www.comet-initiative.org), and 
was presented as a poster at the recent European 
Association of Oral Medicine (EAOM) meeting 
in Turin.18 We hope it will be used to inform 
trials and subsequently reviews in this area.
The COMET initiative is an international 
collaboration which aims to reduce the het-
erogeneity of outcome measurements used 
in trials (www.comet-intiative.org). COMET 
(core outcome measurements in effectiveness 
trials) ‘brings together researchers interested 
in the development and application of agreed 
standardised sets of outcomes, known as a 
‘core outcome set.’ These sets should represent 
the minimum that should be measured and 
reported in all clinical trials, audits of practice or 
other forms of research for a specific condition. 
They do not imply that outcomes in a particular 
study should be restricted to those in the core 
outcome set. Rather, there is an expectation that 
the core outcomes will be collected and reported 
to allow the results of trials and other studies 
to be compared, contrasted and combined as 
appropriate; and that researchers will continue to 
collect and explore other outcomes as well’ (www.
comet-intiative.org). There are a wide variety of 
core outcome sets that have previously been 
developed in areas outside of dentistry. These 
include the CROWN initiative (core outcome 
sets in women’s in newborn health) (http://www.
crown-initiative.org/core-outcome-sets/) and 
OMERACT (outcome measures in rheumatol-
ogy) (https://www.omeract.org).
Using a suggested framework for the devel-
opment of a core outcome set, a three stage 
approach was carried out in the development 
of a core outcome set for recurrent aphthous 
stomatitis (COSRAS):19
• Identifying existing knowledge: a review of 
the existing outcome measures in use
• Stakeholder involvement: the opinions of RAS 
patients with regards to outcome measures
• Consensus methods: Delphi consensus 
process of clinicians involved in managing 
RAS patients.
RAS patients were asked about the outcome 
measures they thought were important and 
this information was combined with the results 
of a systematic review of outcome measures in 
trials of RAS treatments. Removing duplica-
tions, over 300 outcomes were condensed into 
22 broad outcomes; these included the patient 
outcomes of choice. These 22 individual 
outcomes were then presented to oral medicine 
clinicians at a national speciality meeting 
(British Society of Oral Medicine) with the 
aim of gaining consensus on the outcomes to 
be included in a core outcome set.
The difficulty of recruiting adequate 
numbers of participants to clinical trials is 
well-known to any triallist and results in the 
risk of a study being underpowered. The use 
of a core outcome set in oral medicine trials 
makes the possibility of allowing combination 
of the results of different trials in a meta-anal-
ysis a realistic possibility, as well as allowing 
meaningful comparison of different interven-
tions. Ultimately, the strength of the evidence 
base to guide clinical care will be improved.
Conclusion
High-quality research informs clinical guidelines 
and everyday practice. It is important that cli-
nicians maintain up to date knowledge of their 
subject matter in order to provide the best care 
for patients. This is especially important in oral 
medicine as many of the conditions and interven-
tions used to treat have considerable morbidity 
and in some cases mortality. Cochrane systematic 
reviews are a useful tool for evaluating and sum-
marising the evidence for clinicians, however, the 
quality of the evidence produced by the system-
atic reviews is directly related to the quality of 
the trials included. Improvements to the meth-
odology of oral medicine intervention trials as 
described in this paper, the use of patient-related 
outcomes measures (PROMS) and the future 
development and use of core outcome sets should 
improve the quality of the evidence produced to 
inform clinical care.
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